Journal of Neuro-Oncology

, Volume 107, Issue 2, pp 225–232 | Cite as

Primary central nervous system post-transplant lymphoproliferative disorders following allogeneic hematopoietic stem cell transplantation

  • Frank Lieberman
  • Victor Yazbeck
  • Anastasios Raptis
  • Raymond Felgar
  • Michael Boyiadzis
Topic Review


Post-transplant lymphoproliferative disorder (PTLD) is a serious complication after allogeneic hematopoietic stem cell transplantation (HSCT). Extra nodal involvement is common in PTLD, but isolated involvement of the central nervous system (CNS) is extremely rare. Given the rarity of primary CNS-PTLD there is no consensus on optimal treatment. We report a patient who developed Epstein-Barr virus related primary CNS-PTLD following allogeneic HSCT who was treated with the monoclonal anti-CD20 antibody rituximab and reduction of immunosuppression. In addition, we review the literature and discuss treatment options for patients with primary CNS-PTLD following allogeneic HSCT.


Post-transplant lymphoproliferative disorders Hematopoietic stem cell transplantation Central nervous system Rituximab 


Conflict of interest

The authors declare that they have no conflict of interest.


  1. 1.
    Kaushansky K, Williams WJ (2010) Williams hematology. McGraw-Hill Medical, New YorkGoogle Scholar
  2. 2.
    Swerdlow S, Campo E, Lee Harris N, Jaffe ES, Pileri SA, Stein H, Thiele J, Vardiman JW, World Health Orgnization, International Agency for Research on Cancer (2008) WHO classification of tumours of haematopoietic and lymphoid tissues. World Health Organization International Agency for Research on Cancer, LyonGoogle Scholar
  3. 3.
    Gottschalk S, Rooney CM, Heslop HE (2005) Post-transplant lymphoproliferative disorders. Annu Rev Med 56:29–44PubMedCrossRefGoogle Scholar
  4. 4.
    Tsao L, Hsi ED (2007) The clinicopathologic spectrum of posttransplantation lymphoproliferative disorders. Arch Pathol Lab Med 131:1209–1218PubMedGoogle Scholar
  5. 5.
    Cavaliere R, Petroni G, Lopes MB, Schiff D (2010) Primary central nervous system post-transplantation lymphoproliferative disorder: an International Primary Central Nervous System Lymphoma Collaborative Group Report. Cancer 116:863–870PubMedCrossRefGoogle Scholar
  6. 6.
    Landgren O, Gilbert ES, Rizzo JD, Socie G, Banks PM, Sobocinski KA, Horowitz MM, Jaffe ES, Kingma DW, Travis LB, Flowers ME, Martin PJ, Deeg HJ, Curtis RE (2009) Risk factors for lymphoproliferative disorders after allogeneic hematopoietic cell transplantation. Blood 113:4992–5001PubMedCrossRefGoogle Scholar
  7. 7.
    DiNardo CD, Tsai DE (2010) Treatment advances in posttransplant lymphoproliferative disease. Curr Opin Hematol 17:368–374PubMedCrossRefGoogle Scholar
  8. 8.
    Parker A, Bowles K, Bradley JA, Emery V, Featherstone C, Gupte G, Marcus R, Parameshwar J, Ramsay A, Newstead C (2010) Management of post-transplant lymphoproliferative disorder in adult solid organ transplant recipients - BCSH and BTS Guidelines. British journal of haematology 149:693–705PubMedCrossRefGoogle Scholar
  9. 9.
    Evens AM, Roy R, Sterrenberg D, Moll MZ, Chadburn A, Gordon LI (2010) Post-transplantation lymphoproliferative disorders: diagnosis, prognosis, and current approaches to therapy. Current oncology reports 12:383–394PubMedCrossRefGoogle Scholar
  10. 10.
    Aisa Y, Mori T, Nakazato T, Suzuki S, Suzuki N, Ikeda Y, Okamoto S (2009) Primary central nervous system post-transplant lymphoproliferative disorder presenting as cerebral hemorrhage after unrelated bone marrow transplantation. Transpl Infect Dis 11:438–441PubMedCrossRefGoogle Scholar
  11. 11.
    Castellano-Sanchez AA, Li S, Qian J, Lagoo A, Weir E, Brat DJ (2004) Primary central nervous system posttransplant lymphoproliferative disorders. Am J Clin Pathol 121:246–253PubMedCrossRefGoogle Scholar
  12. 12.
    Hamadani M, Martin LK, Benson DM, Copelan EA, Devine SM, Hofmeister CC (2007) Central nervous system post-transplant lymphoproliferative disorder despite negative serum and spinal fluid Epstein-Barr virus DNA PCR. Bone Marrow Transplant 39:249–251PubMedCrossRefGoogle Scholar
  13. 13.
    Kordelas L, Trenschel R, Koldehoff M, Elmaagacli A, Beelen DW (2008) Successful treatment of EBV PTLD with CNS lymphomas with the monoclonal anti-CD20 antibody rituximab. Onkologie 31:691–693PubMedCrossRefGoogle Scholar
  14. 14.
    Nagafuji K, Eto T, Hayashi S, Oshima K, Maeda Y, Gondo H, Inamura T, Niho Y (1998) Donor lymphocyte transfusion for the treatment of Epstein-Barr virus-associated lymphoproliferative disorder of the brain. Bone Marrow Transplant 21:1155–1158PubMedCrossRefGoogle Scholar
  15. 15.
    Nozzoli C, Bartolozzi B, Guidi S, Orsi A, Vannucchi AM, Leoni F, Bosi A (2006) Epstein-Barr virus-associated post-transplant lymphoproliferative disease with central nervous system involvement after unrelated allogeneic hematopoietic stem cell transplantation. Leuk Lymphoma 47:167–169PubMedCrossRefGoogle Scholar
  16. 16.
    Pakakasama S, Eames GM, Morriss MC, Huls MH, Rooney CM, Heslop HE, Krance RA (2004) Treatment of Epstein-Barr virus lymphoproliferative disease after hematopoietic stem-cell transplantation with hydroxyurea and cytotoxic T-cell lymphocytes. Transplantation 78:755–757PubMedCrossRefGoogle Scholar
  17. 17.
    Terasawa T, Ohashi H, Tsushita K, Utsumi M, Mukai E, Nakamura S, Shimoyama M (2002) Failure to detect Epstein-Barr virus (EBV) DNA in plasma by real-time PCR in a case of EBV-associated posttransplantation lymphoproliferative disorder confined to the central nervous system. Int J Hematol 75:416–420PubMedCrossRefGoogle Scholar
  18. 18.
    Verschuur A, Brousse N, Raynal B, Brison O, Rohrlich P, Rahimy C, Vilmer E (1994) Donor B cell lymphoma of the brain after allogeneic bone marrow transplantation for acute myeloid leukemia. Bone Marrow Transplant 14:467–470PubMedGoogle Scholar
  19. 19.
    Heslop HE (2009) How I treat EBV lymphoproliferation. Blood 114:4002–4008PubMedCrossRefGoogle Scholar
  20. 20.
    Gerstner ER, Batchelor TT (2010) Primary central nervous system lymphoma. Arch Neurol 67:291–297PubMedCrossRefGoogle Scholar
  21. 21.
    Taj MM, Messahel B, Mycroft J, Pritchard-Jones K, Baker A, Height S, Hadzic N, Pinkerton CR (2008) Efficacy and tolerability of high-dose methotrexate in central nervous system positive or relapsed lymphoproliferative disease following liver transplant in children. British journal of haematology 140:191–196PubMedCrossRefGoogle Scholar
  22. 22.
    Nabors LB, Palmer CA, Julian BA, Przekwas AM, Kew CE (2009) Isolated central nervous system posttransplant lymphoproliferative disorder treated with high-dose intravenous methotrexate. Am J Transplant 9:1243–1248PubMedCrossRefGoogle Scholar
  23. 23.
    Heslop HE, Slobod KS, Pule MA, Hale GA, Rousseau A, Smith CA, Bollard CM, Liu H, Wu MF, Rochester RJ, Amrolia PJ, Hurwitz JL, Brenner MK, Rooney CM (2010) Long-term outcome of EBV-specific T-cell infusions to prevent or treat EBV-related lymphoproliferative disease in transplant recipients. Blood 115:925–935PubMedCrossRefGoogle Scholar
  24. 24.
    Choquet S, Leblond V, Herbrecht R, Socie G, Stoppa AM, Vandenberghe P, Fischer A, Morschhauser F, Salles G, Feremans W, Vilmer E, Peraldi MN, Lang P, Lebranchu Y, Oksenhendler E, Garnier JL, Lamy T, Jaccard A, Ferrant A, Offner F, Hermine O, Moreau A, Fafi-Kremer S, Morand P, Chatenoud L, Berriot-Varoqueaux N, Bergougnoux L, Milpied N (2006) Efficacy and safety of rituximab in B-cell post-transplantation lymphoproliferative disorders: results of a prospective multicenter phase 2 study. Blood 107:3053–3057PubMedCrossRefGoogle Scholar
  25. 25.
    Choquet S, Oertel S, LeBlond V, Riess H, Varoqueaux N, Dorken B, Trappe R (2007) Rituximab in the management of post-transplantation lymphoproliferative disorder after solid organ transplantation: proceed with caution. Ann Hematol 86:599–607PubMedCrossRefGoogle Scholar
  26. 26.
    Kuehnle I, Huls MH, Liu Z, Semmelmann M, Krance RA, Brenner MK, Rooney CM, Heslop HE (2000) CD20 monoclonal antibody (rituximab) for therapy of Epstein-Barr virus lymphoma after hemopoietic stem-cell transplantation. Blood 95:1502–1505PubMedGoogle Scholar
  27. 27.
    Milpied N, Vasseur B, Parquet N, Garnier JL, Antoine C, Quartier P, Carret AS, Bouscary D, Faye A, Bourbigot B, Reguerre Y, Stoppa AM, Bourquard P, de Hurault Ligny B, Dubief F, Mathieu-Boue A, Leblond V (2000) Humanized anti-CD20 monoclonal antibody (Rituximab) in post transplant B-lymphoproliferative disorder: a retrospective analysis on 32 patients. Ann Oncol 11(1):113–116PubMedCrossRefGoogle Scholar
  28. 28.
    Oertel SH, Verschuuren E, Reinke P, Zeidler K, Papp-Vary M, Babel N, Trappe RU, Jonas S, Hummel M, Anagnostopoulos I, Dorken B, Riess HB (2005) Effect of anti-CD 20 antibody rituximab in patients with post-transplant lymphoproliferative disorder (PTLD). Am J Transplant 5:2901–2906PubMedCrossRefGoogle Scholar
  29. 29.
    Patrick A, Wee A, Hedderman A, Wilson D, Weiss J, Govani M (2011) High-dose intravenous rituximab for multifocal, monomorphic primary central nervous system posttransplant lymphoproliferative disorder. J Neurooncol 103(3):739–743PubMedCrossRefGoogle Scholar
  30. 30.
    Doolittle ND, Jahnke K, Belanger R, Ryan DA, Nance RW Jr, Lacy CA, Tyson RM, Haluska M, Hedrick NA, Varallyay C, Neuwelt EA (2007) Potential of chemo-immunotherapy and radioimmunotherapy in relapsed primary central nervous system (CNS) lymphoma. Leuk Lymphoma 48:1712–1720PubMedCrossRefGoogle Scholar
  31. 31.
    Enting RH, Demopoulos A, DeAngelis LM, Abrey LE (2004) Salvage therapy for primary CNS lymphoma with a combination of rituximab and temozolomide. Neurology 63:901–903PubMedGoogle Scholar
  32. 32.
    Santisteban M, Nieto Y, De la Cruz S, Aristu J, Zubieta JL, Fernandez Hidalgo O (2007) Primary central nervous system lymphoma treated with rituximab plus temozolomide in a second line schedule. Clin Transl Oncol 9:465–467PubMedCrossRefGoogle Scholar
  33. 33.
    Wong ET (2005) Monoclonal antibody therapy for central nervous system lymphomas: an emerging treatment paradigm. Expert opinion on pharmacotherapy 6:1107–1114PubMedCrossRefGoogle Scholar
  34. 34.
    Wong ET, Tishler R, Barron L, Wu JK (2004) Immunochemotherapy with rituximab and temozolomide for central nervous system lymphomas. Cancer 101:139–145PubMedCrossRefGoogle Scholar
  35. 35.
    Akyuz C, Aydin GB, Cila A, Akalan N, Soylemezoglu F, Cengiz M, Yazici N, Buyukpamukcu M (2007) Successful use of intraventricular and intravenous rituximab therapy for refractory primary CNS lymphoma in a child. Leuk Lymphoma 48:1253–1255PubMedCrossRefGoogle Scholar
  36. 36.
    Canova F, Marino D, Trentin C, Solda C, Ghiotto C, Aversa SM (2011) Intrathecal chemotherapy in lymphomatous meningitis. Crit Rev Oncol Hematol 79:127–134PubMedCrossRefGoogle Scholar
  37. 37.
    Rubenstein JL, Combs D, Rosenberg J, Levy A, McDermott M, Damon L, Ignoffo R, Aldape K, Shen A, Lee D, Grillo-Lopez A, Shuman MA (2003) Rituximab therapy for CNS lymphomas: targeting the leptomeningeal compartment. Blood 101:466–468PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC. 2011

Authors and Affiliations

  • Frank Lieberman
    • 1
  • Victor Yazbeck
    • 1
  • Anastasios Raptis
    • 1
  • Raymond Felgar
    • 1
  • Michael Boyiadzis
    • 1
  1. 1.Divisions of Hematology-Oncology, and Hematopathology, University of Pittsburgh Cancer InstituteUniversity of Pittsburgh School of MedicinePittsburghUSA

Personalised recommendations